Physician profile
John Easthope
NPI 1174580328
$9,016.11
in general payments reported to CMS, 2019-2025
34 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,612 · 2020: $839 · 2021: $1,007 · 2022: $1,288 · 2023: $1,381 · 2024: $1,625 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,644.20 | 2019-2025 | |
| Pfizer INC. | $1,098.73 | 2019-2025 | |
| Amgen INC. | $1,021.17 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $857.24 | 2019-2025 | Aveir, Cardiomems, Assurity |
| Astrazeneca Pharmaceuticals Lp | $560.18 | 2019-2025 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $390.32 | 2022-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $321.07 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.14 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $252.61 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $242.92 | 2020-2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.74 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $206.47 | 2019-2024 | Xarelto |
| Medtronic, INC. | $205.42 | 2024-2025 | Azure Xt Dr Mri Surescan, Micra, Linq II |
| Amarin Pharma, INC. | $187.09 | 2019-2021 | |
| Boston Scientific Corporation | $175.00 | 2019-2024 | Emblem Mri S-Icd, Resonate El Icd Vr, Superion Indirect Decompression System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $163.33 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $145.22 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $141.15 | 2022-2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $135.06 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $128.86 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $97.52 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $79.87 | 2021-2023 | Arcalyst |
| Akcea Therapeutics, INC. | $64.64 | 2019-2020 | |
| Biotronik INC. | $63.52 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.52 | 2025 | |
| Medtronic Vascular, INC. | $40.93 | 2019-2020 | |
| Heartflow, INC. | $37.01 | 2024-2025 | |
| Convatec INC. | $31.50 | 2025 | |
| Ionis Pharmaceuticals, INC. | $25.26 | 2025 | Tryngolza |
| Livanova USA, INC. | $24.39 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.47 | 2019 | |
| Lundbeck LLC | $20.43 | 2019 | |
| Philips North America LLC | $19.93 | 2024 | (5044) Mcot |
| Kestra Medical Technology Services, INC. | $16.20 | 2023 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Easthope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.